Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:SRDX's Cash-to-Debt is ranked higher than
97% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. NAS:SRDX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SRDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 50.6  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.83
NAS:SRDX's Equity-to-Asset is ranked higher than
81% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. NAS:SRDX: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SRDX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.74  Med: 0.92 Max: 0.96
Current: 0.83
0.74
0.96
Interest Coverage No Debt
NAS:SRDX's Interest Coverage is ranked higher than
96% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. NAS:SRDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:SRDX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 11.66
Beneish M-Score: -2.83
WACC vs ROIC
6.42%
14.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 21.29
NAS:SRDX's Operating Margin % is ranked higher than
92% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. NAS:SRDX: 21.29 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SRDX' s Operating Margin % Range Over the Past 10 Years
Min: -20.11  Med: 30.13 Max: 47.31
Current: 21.29
-20.11
47.31
Net Margin % 12.88
NAS:SRDX's Net Margin % is ranked higher than
86% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. NAS:SRDX: 12.88 )
Ranked among companies with meaningful Net Margin % only.
NAS:SRDX' s Net Margin % Range Over the Past 10 Years
Min: -35.08  Med: 17.25 Max: 30.9
Current: 12.88
-35.08
30.9
ROE % 9.00
NAS:SRDX's ROE % is ranked higher than
64% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NAS:SRDX: 9.00 )
Ranked among companies with meaningful ROE % only.
NAS:SRDX' s ROE % Range Over the Past 10 Years
Min: -12.91  Med: 10.43 Max: 23.9
Current: 9
-12.91
23.9
ROA % 7.36
NAS:SRDX's ROA % is ranked higher than
81% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. NAS:SRDX: 7.36 )
Ranked among companies with meaningful ROA % only.
NAS:SRDX' s ROA % Range Over the Past 10 Years
Min: -11.85  Med: 8.38 Max: 19.94
Current: 7.36
-11.85
19.94
ROC (Joel Greenblatt) % 70.96
NAS:SRDX's ROC (Joel Greenblatt) % is ranked higher than
89% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. NAS:SRDX: 70.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SRDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -18.72  Med: 85.11 Max: 110.87
Current: 70.96
-18.72
110.87
3-Year Revenue Growth Rate 12.30
NAS:SRDX's 3-Year Revenue Growth Rate is ranked higher than
71% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NAS:SRDX: 12.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SRDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -24.6  Med: 15.45 Max: 57.9
Current: 12.3
-24.6
57.9
3-Year EBITDA Growth Rate 3.70
NAS:SRDX's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. NAS:SRDX: 3.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SRDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -32.7  Med: 14.05 Max: 90.6
Current: 3.7
-32.7
90.6
3-Year EPS without NRI Growth Rate -8.40
NAS:SRDX's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. NAS:SRDX: -8.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SRDX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -35.4  Med: 11.8 Max: 48.3
Current: -8.4
-35.4
48.3
GuruFocus has detected 3 Warning Signs with Surmodics Inc $NAS:SRDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SRDX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:PACB, NAS:OXFD, NAS:NVDQ, NAS:RDNT, NAS:QTNT, NAS:ONVO, NYSE:NVTA, NAS:MGEN, OTCPK:EPGNY, OTCPK:CLIFF, NYSE:ENZ, NAS:AIQ, NAS:TRIB, AMEX:SENS, OTCPK:BMLIF, OTCPK:CBIS, NAS:PMD, NAS:NTRA, NAS:FLDM, NAS:TTOO » details
Traded in other countries:SU6.Germany,
Headquarter Location:USA
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry.

Surmodics Inc was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Its business units are organized and managed in two reportable segments, Medical Device and In Vitro Diagnostics. The core offerings in its Medical Device business unit include surface modification coating technologies that impart lubricity, prohealing or biocompatibility characteristics, or drug delivery capabilities. It manufactures or sells components for in vitro diagnostic immunoassay and molecular tests and it manufactures and sells surface coatings to the diagnostic, biomedical research, and life science markets. The In Vitro Diagnostics products include Protein Stabilizers, Substrates, Recombinant Human Antigens, and Surface Coatings for Molecular Diagnostic Applications.

Ratios

vs
industry
vs
history
PE Ratio 35.49
SRDX's PE Ratio is ranked higher than
50% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.35 vs. SRDX: 35.49 )
Ranked among companies with meaningful PE Ratio only.
SRDX' s PE Ratio Range Over the Past 10 Years
Min: 8.52  Med: 29.34 Max: 584.75
Current: 35.49
8.52
584.75
Forward PE Ratio 96.15
SRDX's Forward PE Ratio is ranked lower than
97% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.63 vs. SRDX: 96.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 35.49
SRDX's PE Ratio without NRI is ranked higher than
51% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.61 vs. SRDX: 35.49 )
Ranked among companies with meaningful PE Ratio without NRI only.
SRDX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.52  Med: 28.95 Max: 584.75
Current: 35.49
8.52
584.75
Price-to-Owner-Earnings 25.70
SRDX's Price-to-Owner-Earnings is ranked higher than
63% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.37 vs. SRDX: 25.70 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SRDX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.81  Med: 34.26 Max: 281.56
Current: 25.7
13.81
281.56
PB Ratio 3.06
SRDX's PB Ratio is ranked higher than
62% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. SRDX: 3.06 )
Ranked among companies with meaningful PB Ratio only.
SRDX' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.03 Max: 7.42
Current: 3.06
0.98
7.42
PS Ratio 4.57
SRDX's PS Ratio is ranked lower than
60% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. SRDX: 4.57 )
Ranked among companies with meaningful PS Ratio only.
SRDX' s PS Ratio Range Over the Past 10 Years
Min: 2.17  Med: 5.19 Max: 13.77
Current: 4.57
2.17
13.77
Price-to-Free-Cash-Flow 34.31
SRDX's Price-to-Free-Cash-Flow is ranked lower than
65% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.66 vs. SRDX: 34.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SRDX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.26  Med: 20.82 Max: 503.11
Current: 34.31
7.26
503.11
Price-to-Operating-Cash-Flow 16.95
SRDX's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.27 vs. SRDX: 16.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SRDX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.99  Med: 16.02 Max: 30.15
Current: 16.95
5.99
30.15
EV-to-EBIT 18.45
SRDX's EV-to-EBIT is ranked higher than
68% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.02 vs. SRDX: 18.45 )
Ranked among companies with meaningful EV-to-EBIT only.
SRDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.7  Med: 15.65 Max: 103.8
Current: 18.45
-37.7
103.8
EV-to-EBITDA 13.83
SRDX's EV-to-EBITDA is ranked higher than
67% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.53 vs. SRDX: 13.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -167.5  Med: 13.1 Max: 66.8
Current: 13.83
-167.5
66.8
PEG Ratio 3.47
SRDX's PEG Ratio is ranked lower than
53% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. SRDX: 3.47 )
Ranked among companies with meaningful PEG Ratio only.
SRDX' s PEG Ratio Range Over the Past 10 Years
Min: 1.32  Med: 3.28 Max: 4.01
Current: 3.47
1.32
4.01
Shiller PE Ratio 51.39
SRDX's Shiller PE Ratio is ranked lower than
65% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.11 vs. SRDX: 51.39 )
Ranked among companies with meaningful Shiller PE Ratio only.
SRDX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.08  Med: 43.3 Max: 132.12
Current: 51.39
17.08
132.12
Current Ratio 8.66
SRDX's Current Ratio is ranked higher than
88% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. SRDX: 8.66 )
Ranked among companies with meaningful Current Ratio only.
SRDX' s Current Ratio Range Over the Past 10 Years
Min: 1.57  Med: 5.92 Max: 18.27
Current: 8.66
1.57
18.27
Quick Ratio 8.17
SRDX's Quick Ratio is ranked higher than
87% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. SRDX: 8.17 )
Ranked among companies with meaningful Quick Ratio only.
SRDX' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 5.43 Max: 18
Current: 8.17
1.49
18
Days Inventory 115.37
SRDX's Days Inventory is ranked lower than
61% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. SRDX: 115.37 )
Ranked among companies with meaningful Days Inventory only.
SRDX' s Days Inventory Range Over the Past 10 Years
Min: 33.96  Med: 123.11 Max: 168.39
Current: 115.37
33.96
168.39
Days Sales Outstanding 34.92
SRDX's Days Sales Outstanding is ranked higher than
84% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. SRDX: 34.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.19  Med: 35.38 Max: 80.51
Current: 34.92
30.19
80.51
Days Payable 61.64
SRDX's Days Payable is ranked higher than
55% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. SRDX: 61.64 )
Ranked among companies with meaningful Days Payable only.
SRDX' s Days Payable Range Over the Past 10 Years
Min: 33.07  Med: 57.73 Max: 166.09
Current: 61.64
33.07
166.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
SRDX's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. SRDX: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.1  Med: 0.9 Max: 8.1
Current: 1.7
-5.1
8.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.70
SRDX's Price-to-Net-Cash is ranked lower than
55% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.61 vs. SRDX: 13.70 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRDX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.9  Med: 24.21 Max: 700
Current: 13.7
3.9
700
Price-to-Net-Current-Asset-Value 9.16
SRDX's Price-to-Net-Current-Asset-Value is ranked higher than
52% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.67 vs. SRDX: 9.16 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRDX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.27  Med: 16.07 Max: 160.14
Current: 9.16
3.27
160.14
Price-to-Tangible-Book 5.36
SRDX's Price-to-Tangible-Book is ranked lower than
51% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.04 vs. SRDX: 5.36 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRDX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.26  Med: 4.61 Max: 18.49
Current: 5.36
1.26
18.49
Price-to-Intrinsic-Value-Projected-FCF 1.12
SRDX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. SRDX: 1.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SRDX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.42 Max: 4.29
Current: 1.12
0.52
4.29
Price-to-Median-PS-Value 0.88
SRDX's Price-to-Median-PS-Value is ranked higher than
64% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. SRDX: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.6 Max: 9.35
Current: 0.88
0.48
9.35
Price-to-Peter-Lynch-Fair-Value 3.91
SRDX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
73% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. SRDX: 3.91 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
SRDX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.83 Max: 31.8
Current: 3.91
0.47
31.8
Price-to-Graham-Number 2.91
SRDX's Price-to-Graham-Number is ranked higher than
57% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. SRDX: 2.91 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SRDX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.91  Med: 2.79 Max: 13.55
Current: 2.91
0.91
13.55
Earnings Yield (Greenblatt) % 5.41
SRDX's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. SRDX: 5.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.7  Med: 5.9 Max: 22
Current: 5.41
-10.7
22
Forward Rate of Return (Yacktman) % 13.34
SRDX's Forward Rate of Return (Yacktman) % is ranked higher than
66% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. SRDX: 13.34 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SRDX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2  Med: 4.9 Max: 36.4
Current: 13.34
2
36.4

More Statistics

Revenue (TTM) (Mil) $73.39
EPS (TTM) $ 0.71
Beta0.71
Short Percentage of Float4.12%
52-Week Range $21.90 - 30.75
Shares Outstanding (Mil)13.28

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 68 71 76
EPS ($) 0.21 0.26 0.32
EPS without NRI ($) 0.21 0.26 0.32
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
Evolent Health, Inc. Announces Pricing of Secondary Public Offering of Class A Common Stock Jun 22 2017 
SEACOR Marine Announces “Stalking Horse” Bid to Form Joint Venture With Montco Offshore, I Jun 22 2017 
Greenbrier announces webcast and conference call of quarterly financial results Jun 22 2017 
NXT Energy Solutions Announces Results of Annual General Meeting Jun 22 2017 
Motif Bio Announces Result of General Meeting and Total Voting Rights Jun 22 2017 
PNC Releases Results Of Annual Dodd-Frank Company-Run Stress Test Jun 22 2017 
Frank’s International N.V. to Participate in Upcoming Investor Conference Jun 22 2017 
M&T Bank Corporation Releases "Company-Run" Dodd-Frank Act Stress Test Results Jun 22 2017 
Western Gas To Present At Upcoming J.P. Morgan Energy Equity Investor Conference Jun 22 2017 
A Nation in Pain: Focus on Medicaid Jun 22 2017 

More From Other Websites
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : May 29, 2017 May 29 2017
Surmodics to Present at Upcoming Investor Conferences May 22 2017
ETFs with exposure to SurModics, Inc. : May 5, 2017 May 05 2017
SurModics, Inc. :SRDX-US: Earnings Analysis: Q2, 2017 By the Numbers : May 3, 2017 May 03 2017
Edited Transcript of SRDX earnings conference call or presentation 27-Apr-17 12:30pm GMT May 01 2017
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : April 28, 2017 Apr 28 2017
SurModics posts 2Q profit Apr 27 2017
Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance Apr 27 2017
SurModics, Inc. – Value Analysis (NASDAQ:SRDX) : April 19, 2017 Apr 19 2017
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : April 18, 2017 Apr 18 2017
Surmodics to Webcast Second Quarter 2017 Earnings Conference Call on April 27 Apr 18 2017
Surmodics Appoints Lisa Wipperman Heine to Its Board of Directors Apr 17 2017
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : March 20, 2017 Mar 20 2017
Surmodics to Present at Oppenheimer Healthcare Conference Mar 14 2017
Why Is Surmodics (SRDX) Down 2.7% Since the Last Earnings Report? Mar 08 2017
SurModics, Inc. breached its 50 day moving average in a Bearish Manner : SRDX-US : March 6, 2017 Mar 06 2017
SurModics, Inc. :SRDX-US: Earnings Analysis: Q1, 2017 By the Numbers : February 15, 2017 Feb 15 2017
Surmodics Announces 2017 Annual Shareholders Meeting Feb 09 2017
SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1 Feb 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}